• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

When statins aren’t enough, this drug may help lower ‘bad’ cholesterol

May 8, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
When statins aren't enough, this drug may help lower 'bad' cholesterol
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


by I. Edwards

When statins aren't enough, this drug may help lower 'bad' cholesterol

A new drug combo lowers “bad” LDL cholesterol for people whose levels remain high even after taking statins. The new pill pairs a new drug called obicetrapib with an existing one, ezetimibe. In a Phase 3 clinical trial, this combo reduced LDL levels by nearly 49% over about three months, according to Cleveland Clinic researchers.

The results were presented on Wednesday at the European Atherosclerosis Society meeting in Glasgow, Scotland, and simultaneously published in The Lancet.

“High LDL is one of the leading risk factors for heart disease, and we have such a poor handle on controlling that risk,” Dr. Corey Bradley, a cardiologist at Columbia University, told NBC News. “Many people have such a high LDL they will require multiple agents to control it.”

The trial included 407 people with an average age of 68. Even though they were taking cholesterol-lowering medications, everyone had LDL levels above 70 mg/dL. Researchers divided participants into four groups: One took the combo pill; two groups took each drug separately; and another group took a placebo. All participants continued their usual cholesterol medications.

Dr. Ashish Sarraju, a preventive cardiologist at the Cleveland Clinic, led the study.

“We need to give patients and their doctors all the options we can to try to get LDL under control if they are at risk for—or already have—cardiovascular disease,” Sarraju said. “In higher-risk patients, you want to get LDL down as quickly as possible and keep it there as long as possible.”

High-risk patients are those who have had a stroke or heart attack, or are likely to have one. Even high-intensity statins are sometimes not enough to bring LDL to safe levels.

The American Heart Association (AHA) recommends keeping LDL below 100 mg/dL, and under 70 mg/dL for high-risk patients.

NewAmsterdam Pharma, the Dutch company that makes obicetrapib, plans to speak with the U.S. Food and Drug Administration (FDA) “over the course of the year,” about possible approval of the combo drug, a spokesperson told NBC News.

In the past, some similar drugs have not worked. Dr. Robert Rosenson of Mount Sinai Health System noted that some drugs in this class have failed to prevent strokes or heart attacks. “But I am cautiously hopeful,” he said.

NewAmsterdam Pharma is now running another trial to see if the combo drug not only lowers cholesterol but also protects against major heart events.

While lifestyle changes like eating healthily, exercising and avoiding smoking can help lower LDL, many people still struggle to reach safe levels. Only about 20% of patients are able to manage their LDL, said Bradley, of Columbia.

More information:
Ashish Sarraju et al, Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial, The Lancet (2025). DOI: 10.1016/S0140-6736(25)00721-4

The Mayo Clinic has more on lifestyle changes to improve your cholesterol.

2025 HealthDay. All rights reserved.

Citation:
When statins aren’t enough, this drug may help lower ‘bad’ cholesterol (2025, May 8)
retrieved 8 May 2025
from https://medicalxpress.com/news/2025-05-statins-drug-bad-cholesterol.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



by I. Edwards

When statins aren't enough, this drug may help lower 'bad' cholesterol

A new drug combo lowers “bad” LDL cholesterol for people whose levels remain high even after taking statins. The new pill pairs a new drug called obicetrapib with an existing one, ezetimibe. In a Phase 3 clinical trial, this combo reduced LDL levels by nearly 49% over about three months, according to Cleveland Clinic researchers.

The results were presented on Wednesday at the European Atherosclerosis Society meeting in Glasgow, Scotland, and simultaneously published in The Lancet.

“High LDL is one of the leading risk factors for heart disease, and we have such a poor handle on controlling that risk,” Dr. Corey Bradley, a cardiologist at Columbia University, told NBC News. “Many people have such a high LDL they will require multiple agents to control it.”

The trial included 407 people with an average age of 68. Even though they were taking cholesterol-lowering medications, everyone had LDL levels above 70 mg/dL. Researchers divided participants into four groups: One took the combo pill; two groups took each drug separately; and another group took a placebo. All participants continued their usual cholesterol medications.

Dr. Ashish Sarraju, a preventive cardiologist at the Cleveland Clinic, led the study.

“We need to give patients and their doctors all the options we can to try to get LDL under control if they are at risk for—or already have—cardiovascular disease,” Sarraju said. “In higher-risk patients, you want to get LDL down as quickly as possible and keep it there as long as possible.”

High-risk patients are those who have had a stroke or heart attack, or are likely to have one. Even high-intensity statins are sometimes not enough to bring LDL to safe levels.

The American Heart Association (AHA) recommends keeping LDL below 100 mg/dL, and under 70 mg/dL for high-risk patients.

NewAmsterdam Pharma, the Dutch company that makes obicetrapib, plans to speak with the U.S. Food and Drug Administration (FDA) “over the course of the year,” about possible approval of the combo drug, a spokesperson told NBC News.

In the past, some similar drugs have not worked. Dr. Robert Rosenson of Mount Sinai Health System noted that some drugs in this class have failed to prevent strokes or heart attacks. “But I am cautiously hopeful,” he said.

NewAmsterdam Pharma is now running another trial to see if the combo drug not only lowers cholesterol but also protects against major heart events.

While lifestyle changes like eating healthily, exercising and avoiding smoking can help lower LDL, many people still struggle to reach safe levels. Only about 20% of patients are able to manage their LDL, said Bradley, of Columbia.

More information:
Ashish Sarraju et al, Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial, The Lancet (2025). DOI: 10.1016/S0140-6736(25)00721-4

The Mayo Clinic has more on lifestyle changes to improve your cholesterol.

2025 HealthDay. All rights reserved.

Citation:
When statins aren’t enough, this drug may help lower ‘bad’ cholesterol (2025, May 8)
retrieved 8 May 2025
from https://medicalxpress.com/news/2025-05-statins-drug-bad-cholesterol.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Man gored by bison in year’s first attack by Yellowstone’s most dangerous wild animal

Related Posts

Understanding the Impact of Aging on Eye Health: Prevention and Treatment Options

May 8, 2025
5
Chipiron raises $17M for miniature MRI prototype

Chipiron raises $17M for miniature MRI prototype

May 8, 2025
7
  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Man gored by bison in year's first attack by Yellowstone's most dangerous wild animal

Man gored by bison in year’s first attack by Yellowstone’s most dangerous wild animal

May 8, 2025
Why is the U.S. bombing Yemen? : The NPR Politics Podcast : NPR

Why is the U.S. bombing Yemen? : The NPR Politics Podcast : NPR

May 8, 2025
The Manila Times

Stricter laws vs reckless drivers sought

May 8, 2025
Instrumentalizing Soviets' victory over Nazi Germany – DW – 05/08/2025

Instrumentalizing Soviets’ victory over Nazi Germany – DW – 05/08/2025

May 8, 2025

Recent News

Man gored by bison in year's first attack by Yellowstone's most dangerous wild animal

Man gored by bison in year’s first attack by Yellowstone’s most dangerous wild animal

May 8, 2025
0
Why is the U.S. bombing Yemen? : The NPR Politics Podcast : NPR

Why is the U.S. bombing Yemen? : The NPR Politics Podcast : NPR

May 8, 2025
4
The Manila Times

Stricter laws vs reckless drivers sought

May 8, 2025
4
Instrumentalizing Soviets' victory over Nazi Germany – DW – 05/08/2025

Instrumentalizing Soviets’ victory over Nazi Germany – DW – 05/08/2025

May 8, 2025
4

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Man gored by bison in year's first attack by Yellowstone's most dangerous wild animal

Man gored by bison in year’s first attack by Yellowstone’s most dangerous wild animal

May 8, 2025
Why is the U.S. bombing Yemen? : The NPR Politics Podcast : NPR

Why is the U.S. bombing Yemen? : The NPR Politics Podcast : NPR

May 8, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co